| 8.96 0.29 (3.34%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.15 | 1-year : | 12.57 |
| Resists | First : | 9.55 | Second : | 10.77 |
| Pivot price | 8.37 |
|||
| Supports | First : | 7.57 | Second : | 6.3 |
| MAs | MA(5) : | 8.75 |
MA(20) : | 8.44  |
| MA(100) : | 11.24 |
MA(250) : | 10.12 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 74.3 |
D(3) : | 75 |
| RSI | RSI(14): 52.6 |
|||
| 52-week | High : | 16.19 | Low : | 5.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RGNX ] has closed below upper band by 10.4%. Bollinger Bands are 52.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.01 - 9.06 | 9.06 - 9.11 |
| Low: | 8.28 - 8.35 | 8.35 - 8.4 |
| Close: | 8.86 - 8.96 | 8.96 - 9.05 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Thu, 09 Apr 2026
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
Thu, 09 Apr 2026
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Thu, 09 Apr 2026
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Tue, 07 Apr 2026
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline i - GuruFocus
Tue, 07 Apr 2026
RGNX Technical Analysis | Trend, Signals & Chart Patterns | REGENXBIO INC (NASDAQ:RGNX) - ChartMill
Mon, 06 Apr 2026
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securitie - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 81.1 (%) |
| Shares Short | 6,470 (K) |
| Shares Short P.Month | 6,000 (K) |
| EPS | -3.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.01 |
| Profit Margin | -113.8 % |
| Operating Margin | -190 % |
| Return on Assets (ttm) | -22 % |
| Return on Equity (ttm) | -107 % |
| Qtrly Rev. Growth | 43 % |
| Gross Profit (p.s.) | -1.52 |
| Sales Per Share | 3.3 |
| EBITDA (p.s.) | -2.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -124 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -2.39 |
| PEG Ratio | 0 |
| Price to Book value | 4.43 |
| Price to Sales | 2.71 |
| Price to Cash Flow | -3.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|